Nigel Rudd Buys 1,240,000 Shares of Destiny Pharma plc (LON:DEST) Stock

Destiny Pharma plc (LON:DEST) insider Nigel Rudd purchased 1,240,000 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was bought at an average cost of GBX 0.25 ($0.00) per share, for a total transaction of £3,100 ($3,961.66).

Destiny Pharma Trading Up 12.9 %

LON DEST opened at GBX 4.80 ($0.06) on Wednesday. Destiny Pharma plc has a 1 year low of GBX 2 ($0.03) and a 1 year high of GBX 84 ($1.07). The company has a market cap of £4.57 million, a PE ratio of -82.50 and a beta of 0.31. The stock’s 50-day moving average price is GBX 8.88 and its two-hundred day moving average price is GBX 23.57.

Analyst Upgrades and Downgrades

Separately, Shore Capital restated a “house stock” rating on shares of Destiny Pharma in a report on Monday, July 15th.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.